# US 2016/0355811 A1 · Antisense Oligonucleotides for Treatment of Spinal Muscular Atrophy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355811 A1
- Document ID: US20160355811A1
- Status: Published application
- Kind: A1
- Application number: 15/117,758
- Filed: 2015-02-10
- Published: 2016-12-08
- Earliest claimed: 2014-02-10
- Assignees: Ohio State Innovation Foundation
- Applicants: Ohio State Innovation Foundation
- Inventors: Arthur Burghes; Vicki McGovern; Thomas Prior
- Web page: https://patentgrep.com/patent/US20160355811A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 2310/11: Antisense
- C12N 2310/314: Phosphoramidates
- C12N 2310/3233: Morpholino-type ring
- C12N 2320/33: Alteration of splicing
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Various aspects of the present invention are directed to compounds targeted to various regions of the survival motor neuron 2 (SMN2) gene. Such compounds may be used to increase incorporation of exon 7 in processed transcripts of SMN2. Such compounds may therefore be useful in increasing the amount of full-length SMN protein produced by the SMN2 gene. As such, these compounds may provide a therapeutic approach for treatment of spinal muscular atrophy (SMA).

## Claims

### Claim 1

An antisense oligonucleotide having a nucleotide sequence that is complementary to a portion of a sequence of intron 6, intron 7, or exon 7 of a survival motor neuron (SMN) 2 gene, the nucleotide sequence of the antisense oligonucleotide being chosen from [SEQ ID NO 1], [SEQ ID NO 2], [SEQ ID NO 4], [SEQ ID NO 5], [SEQ ID NO 6], [SEQ ID NO 7], [SEQ ID NO 8], [SEQ ID NO 9], [SEQ ID NO 10], [SEQ ID NO 11], [SEQ ID NO 12], [SEQ ID NO 13], [SEQ ID NO 14], [SEQ ID NO 15], [SEQ ID NO 16], and [SEQ ID NO 17].

### Claim 2 (depends on 1)

The antisense oligonucleotide of claim 1, wherein each nucleoside of the antisense oligonucleotide are linked to a morpholino ring.

### Claim 3 (depends on 2)

The antisense oligonucleotide of claim 2, wherein morpholino rings are linked to one another via phosphorodiamidate groups.

### Claim 4 (depends on 1)

The antisense oligonucleotide of claim 1, wherein the nucleotide sequence is targeted to a cis splicing regulatory element.

### Claim 5 (depends on 4)

The antisense oligonucleotide of claim 4, wherein the cis splicing regulatory element is chosen from an exonic splicing enhancer, an exonic splicing silencer, an intronic splicing enhancer, and an intronic splicing silencer.

### Claim 6 (depends on 4)

The antisense oligonucleotide of claim 4, wherein the cis splicing regulatory element is an intronic splicing silencer.

### Claim 7 (depends on 1)

The antisense oligonucleotide of claim 1, wherein the nucleotide sequence of the antisense oligonucleotide is complementary to a continuous portion of a sequence of intron 6, intron 7, or exon 7 of a survival motor neuron (SMN) 2 gene.

### Claim 8 (depends on 1)

The antisense oligonucleotide of claim 1, wherein the nucleotide sequence of the antisense oligonucleotide is complementary to a non-continuous portion of a sequence of intron 6, intron 7, or exon 7 of a survival motor neuron (SMN) 2 gene.

### Claim 9

A method of incorporating exon 7 of the SMN2 gene into transcripts of the SMN2 gene, the method comprising:
administering to a subject an antisense oligonucleotide having a nucleotide sequence that is chosen from:
(i) [SEQ ID NO 1], [SEQ ID NO 2], [SEQ ID NO 4], [SEQ ID NO 5], [SEQ ID NO 6], [SEQ ID NO 7], [SEQ ID NO 8], [SEQ ID NO 9], [SEQ ID NO 10], [SEQ ID NO 11], [SEQ ID NO 12], [SEQ ID NO 13], [SEQ ID NO 14], [SEQ ID NO 15], [SEQ ID NO 16], and [SEQ ID NO 17]; or
(ii) which is sufficiently homologous to [SEQ ID NO 1], [SEQ ID NO 2], [SEQ ID NO 4], [SEQ ID NO 5], [SEQ ID NO 6], [SEQ ID NO 7], [SEQ ID NO 8], [SEQ ID NO 9], [SEQ ID NO 10], [SEQ ID NO 11], [SEQ ID NO 12], [SEQ ID NO 13], [SEQ ID NO 14], [SEQ ID NO 15], [SEQ ID NO 16], or [SEQ ID NO 17] such that the antisense oligonucleotide is complementary to a portion of a sequence of intron 6, intron 7, or exon 7 of the SMN2 gene.

### Claim 10 (depends on 9)

The method of claim 9, wherein each nucleoside of the antisense oligonucleotide are linked to a morpholino ring.

### Claim 11 (depends on 10)

The method of claim 10, wherein morpholino rings are linked to one another via phosphorodiamidate groups.

### Claim 12 (depends on 9)

The method of claim 9, wherein the nucleotide sequence is targeted to a cis splicing regulatory element.

### Claim 13 (depends on 12)

The method of claim 12, wherein the cis splicing regulatory element is chosen from an exonic splicing enhancer, an exonic splicing silencer, an intronic splicing enhancer, and an intronic splicing silencer.

### Claim 14 (depends on 12)

The method of claim 12, wherein the cis splicing regulatory element is an intronic splicing silencer.

### Claim 15 (depends on 9)

The method of claim 9, wherein the nucleotide sequence of the antisense oligonucleotide is complementary to a continuous portion of a sequence of intron 6, intron 7, or exon 7 of a survival motor neuron (SMN) 2 gene.

### Claim 16 (depends on 9)

The method of claim 9, wherein the nucleotide sequence of the antisense oligonucleotide is complementary to a non-continuous portion of a sequence of intron 6, intron 7, or exon 7 of a survival motor neuron (SMN) 2 gene.

### Claim 17

A composition for promoting the incorporation of exon 7 of the SMN2 gene into transcripts of the SMN2 gene, the composition comprising:
at least a first antisense oligonucleotide having a nucleotide sequence that is chosen from:
(i) [SEQ ID NO 1], [SEQ ID NO 2], [SEQ ID NO 4], [SEQ ID NO 5], [SEQ ID NO 6], [SEQ ID NO 7], [SEQ ID NO 8], [SEQ ID NO 9], [SEQ ID NO 10], [SEQ ID NO 11], [SEQ ID NO 12], [SEQ ID NO 13], [SEQ ID NO 14], [SEQ ID NO 15], [SEQ ID NO 16], and [SEQ ID NO 17]; or
(ii) which is sufficiently homologous to [SEQ ID NO 1], [SEQ ID NO 2], [SEQ ID NO 4], [SEQ ID NO 5], [SEQ ID NO 6], [SEQ ID NO 7], [SEQ ID NO 8], [SEQ ID NO 9], [SEQ ID NO 10], [SEQ ID NO 11], [SEQ ID NO 12], [SEQ ID NO 13], [SEQ ID NO 14], [SEQ ID NO 15], [SEQ ID NO 16], or [SEQ ID NO 17] such that the antisense oligonucleotide is complementary to a portion of a sequence of intron 6, intron 7, or exon 7 of the SMN2 gene.

### Claim 18 (depends on 17)

The composition of claim 17, further comprising a second antisense oligonucleotide.

### Claim 19 (depends on 18)

The composition of claim 18, wherein the first antisense oligonucleotide and the second antisense oligonucleotide are each targeted to the same nucleic acid target.

### Claim 20 (depends on 18)

The composition of claim 18, wherein the first antisense oligonucleotide and the second antisense oligonucleotide are each targeted to different nucleic acid targets.
